← Back to headlines
Haemonetics Corporation Q3 Performance Leads to Baird Price Target Reduction
Haemonetics Corporation's (HAE) Q3 performance prompted Baird to update its model and lower the price target to $81.
18 Feb, 06:13 — 18 Feb, 06:13
Sources
Showing 1 of 1 sources
